Plant Sterols and Stanols (Phytosterols) for Cholesterol

Proven to lower LDL. Not proven to prevent heart attacks.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not to replace medical care.

In brief: Plant sterols reliably lower LDL cholesterol by roughly 6 to 12%, an effect documented across more than 100 randomized trials and recognized by an FDA-authorized health claim that most supplements never approach. But no randomized trial has ever tested whether plant sterols prevent heart attacks, strokes, or cardiovascular deaths, and lowering a cholesterol number is not the same as lowering risk. The strongest argument in their favor — that absorption-based LDL lowering with the prescription drug ezetimibe does reduce events — is an argument by analogy, not direct evidence, and it is weakened by the small size of the plant sterol effect and an unresolved question about whether circulating plant sterols themselves carry risk. On the evidence, the rationale is strongest for a borderline LDL at low cardiovascular risk used within a lifestyle approach, and weakest wherever meaningful LDL reduction is actually needed, where better-studied options exist. Whether any of this applies to a given person is a decision for them and their clinician, not a conclusion this article reaches for anyone.

Lowers LDL, Never Tested Against Heart Attacks

Plant sterols lower one of the most important cardiovascular biomarkers — LDL cholesterol — and have never been shown to prevent a single heart attack, stroke, or cardiovascular death. That one sentence is the whole article. The LDL effect is real, reproducible across more than 100 randomized trials, and recognized by the FDA; what is missing is the randomized outcome trial that would connect “lowers LDL” to “prevents events.” That trial has never been run — and because plant sterols cannot be patented, the hundreds of millions of dollars a definitive cardiovascular outcome trial would cost are unlikely ever to be invested, so the gap is likely to persist.

Where the Evidence Is Strongest, and Where It Runs Out

For most people, the rationale for plant sterols runs out at the LDL number. The profile where it is strongest is narrow: a borderline LDL in someone at low cardiovascular risk, used within a lifestyle approach, in a situation where a clinician and patient have together concluded that drug therapy is not yet appropriate. There, a modest LDL reduction at the margin displaces nothing more important.

The rationale is weaker for everyone else. At meaningful cardiovascular risk, already on a statin with LDL above goal, statin-intolerant and needing real LDL reduction, or living with familial hypercholesterolemia, the evidence points toward better-studied options. Here the central concern is worth stating plainly: the danger is rarely that plant sterols are toxic — it is the belief that a modest LDL reduction from an unproven supplement provides the same protection as therapies that have actually been shown to prevent heart attacks and strokes. A lab value improves; the protection it is taken to represent has not been demonstrated.

Sitosterolemia, a rare genetic disorder, is the exception in the other direction — in that condition plant sterols are harmful rather than merely unhelpful, as the safety section explains.

None of this maps cleanly onto any individual. Which category a person belongs in, and what to do about it, is a determination for them and their clinician; this article describes what the evidence does and does not show, not what any reader should do.

Find Your Situation

This table maps what the evidence supports for specific profiles. Each row is examined in the sections that follow. (1,2,9,13)

What Plant Sterols and Stanols Are

Plant sterols are compounds found in vegetable oils, nuts, seeds, grains, fruits, and vegetables, structurally close to cholesterol. Plant stanols are their saturated derivatives; they behave similarly, are absorbed even less from the gut, and lower LDL to a comparable degree. The two are usually discussed together under the umbrella term phytosterols, and “plant sterols” here refers to both unless noted.

They lower LDL by competing with cholesterol for absorption. Both pass through the same gateway in the small intestine — the NPC1L1 (Niemann-Pick C1-Like 1) transporter — and when plant sterols are present in the gut alongside dietary and biliary cholesterol, some cholesterol is displaced from absorption and leaves the body unabsorbed. (5,6) Less cholesterol reaches the liver, the liver pulls more LDL from the blood, and circulating LDL falls. Natural diets supply only a few hundred milligrams of phytosterols a day — far below the therapeutic range — so the effect requires fortified foods or supplements to reach. (6)

How Much They Lower LDL

A 2014 meta-analysis of 124 randomized trials established the size and shape of the effect: across intakes of roughly 0.6 to 3.3 grams a day, plant sterols lowered LDL by about 6 to 12% on average, with a clear dose-response that flattens near 3 grams a day. (1) The figures below are drawn from that analysis and corroborated by the European Atherosclerosis Society consensus and the Mayo review, both of which place the common 2-gram target at an 8 to 10% reduction. (1,2,5) In concrete terms the effect is small: an LDL of 160 mg/dL would typically fall by roughly 10 to 19 mg/dL — to somewhere around 145 to 150.

For scale, moderate-intensity statins lower LDL by about 30 to 49%, and high-intensity statins by 50% or more. (13) A concrete example is the head-to-head STELLAR trial, which compared four statins across their dose ranges in roughly 2,400 patients: over six weeks, LDL fell by about 28–46% with simvastatin, 37–51% with atorvastatin, and 46–55% with rosuvastatin. (15) Plant sterols operate in a different range entirely — their 6 to 12% is roughly a quarter to a third of a single statin’s effect.

The effect also has built-in limits. As cholesterol absorption drops, the liver compensates by making more of its own, which is why doubling the dose does not double the result. (2,5) Response also varies widely between people: some respond well, a substantial minority respond minimally, and a few show little change or even a slight rise — differences driven largely by genetics and by how much cholesterol a given person absorbs versus makes. (2,5) For a non-responder, continued use offers nothing. And an LDL persistently above 190 mg/dL raises the possibility of familial hypercholesterolemia, which calls for formal cardiovascular risk assessment rather than self-managed plant sterols.

A note on ApoB. Article 4 introduced ApoB, the protein carried on each LDL particle; because it counts atherogenic particles directly, it is a more precise measure of risk than the LDL cholesterol concentration alone. (10) Plant sterols do lower ApoB, not only LDL cholesterol — kinetic studies show a reduced apoB-100 transport rate — though far fewer such studies exist than for statins. (2) That is worth stating plainly because it removes a tempting escape hatch: the problem with plant sterols is not that they move the wrong number. They move the right ones. The problem is what moving them by this much, through this mechanism, has and has not been shown to do.

The FDA Health Claim, and What It Doesn’t Mean

Plant sterols carry an FDA-authorized health claim — a real regulatory designation, and a routinely misread one. In the agency’s codified language, foods containing at least 0.65 grams per serving of plant sterol esters, eaten twice a day with meals for a daily total of at least 1.3 grams, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease. (7) Plant stanol esters carry the same claim at a higher threshold — 1.7 grams per serving, 3.4 grams daily. (7)

The claim does two things and not a third. It clears a higher bar than the “supports heart health” structure/function language on most supplement labels — Article 2 covers the difference — because an authorized health claim requires “significant scientific agreement” before the FDA permits the wording. But it is not a drug approval: it rests on consistent LDL lowering under specified conditions, not on cardiovascular outcome trials, which for plant sterols have never been run. The FDA authorized a statement about an LDL effect, not a finding that plant sterols prevent heart attacks.

The contrast Article 4 supplies makes the gap concrete. Prescription icosapent ethyl, a high-dose omega-3, carries an FDA drug approval for cardiovascular risk reduction granted on the strength of a randomized outcome trial. Plant sterols carry a health claim granted on the strength of a biomarker. Both are genuine regulatory recognitions. They are not the same kind of recognition.

Where Guidelines Stand

Plant sterols sit in an unusual spot. Unlike most supplements in this series, they have both a regulatory designation and recognition from major lipid societies — but recognition as a dietary LDL-lowering adjunct, not as a therapy for preventing cardiovascular events.

The European Atherosclerosis Society consensus is the most detailed. It concludes that plant sterol or stanol foods may be considered in three situations: in people with high cholesterol at low or intermediate risk who do not qualify for drug therapy; as an add-on for higher-risk or statin-intolerant patients not reaching LDL goals; and in familial hypercholesterolemia, in line with existing guidance. In the same document the panel states plainly that there are no randomized outcome trials with hard endpoints to establish clinical benefit, and that such trials in lower-risk groups are not practically feasible. (2) The recognition is for the LDL effect, explicitly hedged on outcomes.

The US 2018 AHA/ACC cholesterol guideline does not place plant sterols in the foundational management of elevated LDL or established cardiovascular risk; that algorithm runs through statins, then ezetimibe, then PCSK9 inhibitors, all of which carry outcome evidence. (13) Where US society documents mention plant sterols, it is as a dietary option within lifestyle management, not as an alternative to proven drugs when those are indicated. Across both sides of the Atlantic, the pattern is the same: recognized as a way to lower LDL as part of lifestyle, not recommended as a way to prevent cardiovascular events.

The Trial Landscape

The biomarker evidence for plant sterols is among the strongest for any supplement in this series. The outcome evidence, for plant sterols specifically, does not exist. The table shows what is and is not in the record.

Two things jump out. The biomarker column is full and consistent. The cell where a plant sterol outcome trial should sit is empty. A 2023 systematic review in Nutrients confirmed it directly: to date, no randomized placebo-controlled trial has tested plant sterol supplementation against hard cardiovascular endpoints. (9)

That absence needs reading carefully. It does not mean plant sterols have been shown to fail. It means the question of whether they reduce events has not been asked at the scale that would answer it — the difference between “tested and didn’t work” and “never properly tested.” Plant sterols are in the second category. That is a reason for caution before substituting them for proven therapy, not grounds for calling the LDL effect meaningless.

The nearest outcome data come from a different molecule. Ezetimibe is a prescription drug that, like plant sterols, blocks cholesterol absorption at the NPC1L1 transporter. ENHANCE (2008) added it to simvastatin in 720 patients with familial hypercholesterolemia; despite lowering LDL substantially more than simvastatin alone (58% versus 41% at two years), it did not slow thickening of the carotid artery wall on imaging. (3) That null result raised early doubts. IMPROVE-IT (2015) settled them: in 18,144 patients after acute coronary syndrome, adding ezetimibe to a statin cut the seven-year event rate from 34.7% to 32.7% — an absolute reduction of about two percentage points, hazard ratio 0.94, over a median of roughly six years of follow-up. (4) The benefit was modest, driven by fewer heart attacks and strokes, with no difference in mortality, but it was real.

That ezetimibe story is the best case for plant sterols, and it is worth taking seriously — which the next section does. It is also why the trial that would settle the plant sterol question may never run: the compounds are not patentable, already carry an authorized claim, and a multi-year outcome trial in low-risk people is expensive and, the EAS panel judged, impractical. (2) The unanswered question is likely to stay unanswered.

The Strongest Case for Plant Sterols — and Why It Falls Short

The serious argument for plant sterols is not the hand-waving one (“it lowers cholesterol, so it must help”). It is this: LDL is causally tied to atherosclerosis, and lowering it through cholesterol-absorption blockade is a mechanism that has been tested and works. Ezetimibe proves the principle in IMPROVE-IT. And a large 2016 meta-analysis pushes further — across statins and the nonstatin therapies that lower LDL by upregulating the LDL receptor (diet, bile-acid binders, ileal bypass, and ezetimibe), the risk reduction per unit of LDL lowered was essentially the same: about a 23% drop in major vascular events per 1 mmol/L, statistically indistinguishable between the groups. (11) Plant sterols lower LDL through that same receptor-upregulating route. By that logic, their LDL reduction should buy proportional benefit.

That is the strongest case, and it is genuinely strong. It is also not proof, for three reasons that compound.

The inference it invites — ezetimibe works, so plant sterols must work — is exactly the one to resist, because the two share a pathway but not an evidence base:

Plant sterols ─┐

                 ├─► same pathway: block cholesterol at NPC1L1 ─► LDL falls

  Ezetimibe ─────┘

  …but the evidence does not match:

     Plant sterols → 6–12% LDL drop  → NO outcome trial

     Ezetimibe     → ~18–24% LDL drop → proven (IMPROVE-IT)

First, magnitude. The 2016 analysis describes benefit per unit of LDL lowered. Plant sterols lower LDL by a small amount — roughly 0.3 mmol/L, about 12 mg/dL, at typical doses, and somewhat more at higher baseline LDL. Even if the per-unit relationship held exactly, the expected absolute benefit would be modest, and modest benefit in a low-risk person is a small number made smaller.

Second, the analogy is not the evidence. Ezetimibe was tested directly, in tens of thousands of patients, with events counted. Plant sterols were not included in that analysis and have never been tested the same way. Inferring benefit from a related drug is a reasonable hypothesis; it is the hypothesis an outcome trial exists to confirm or refute, and for plant sterols that trial is missing.

Third — and this is where plant sterols and ezetimibe genuinely diverge — ezetimibe is not itself a sterol. It blocks absorption and is cleared. Plant sterols are absorbed in small amounts and circulate, and there is a real, unresolved question about whether elevated circulating plant sterols are themselves atherogenic. The extreme case, sitosterolemia, shows what large accumulations do: premature atherosclerosis. At ordinary supplemented levels the data are genuinely mixed — some observational studies link higher circulating sterols to cardiovascular risk, while the largest pooled analysis, covering 17 observational studies and more than 11,000 people, found no significant association. (8,9) The honest reading is not “plant sterols are dangerous.” It is that a question hangs over them that does not hang over the drug used to argue on their behalf.

Set against this, the niacin and homocysteine stories from Article 1 are a useful reminder of a different failure: there, the marker that moved was the wrong marker — HDL, homocysteine — and moving it did nothing. Plant sterols are not that case. They move LDL, the right marker. Their problem is the combination above: a small move, no direct trial, and a safety question specific to the molecule. A 6 to 12% LDL reduction from an untested supplement is not interchangeable with a 30%-or-more reduction from a statin backed by decades of outcome trials, even when both push the same number the same direction.

Statins, for their part, may do more than lower LDL — they also reduce inflammation and appear to stabilize plaque, effects plant sterols do not share. (12) How much those additional effects contribute to outcomes is debated; much of the statin benefit tracks LDL lowering itself. (11) Either way, the comparison does not rescue plant sterols, because the gap that matters is not statin pleiotropy. It is the absent trial.

Plant Sterols Versus Ezetimibe

For someone considering plant sterols precisely because they cannot or will not take a statin, the comparison that matters most is with ezetimibe — the same mechanism, far better evidenced. (4)

For a statin-intolerant patient who needs meaningful LDL reduction, ezetimibe offers more lowering, an outcome trial, and comparable or lower cost; bempedoic acid and PCSK9 inhibitors are further options depending on risk. Plant sterols are not the default non-statin choice in practice, and anyone going down a non-statin path is owed an accurate picture of the alternatives.

Two Example Patients

Both are composites — not real individuals — built from the populations and trials reviewed here. They are meant to show how the same product produces different answers, not to direct any reader’s decision.

Patient A is 48, with no cardiovascular disease, no diabetes, blood pressure 118/76, LDL 138 mg/dL, and an ApoB consistent with that LDL. Her 10-year ASCVD risk is low. After a discussion with her physician, lifestyle came first and no statin was recommended. She eats well, exercises, and wonders whether plant sterols fit into her dietary approach. This is the profile where the evidence for plant sterols is least weak. The LDL effect is real, her risk is low enough that a marginal reduction displaces nothing more important, and no statin she clinically needs is being delayed. In that setting plant sterols would function as one component of a lifestyle approach — alongside reduced saturated fat, soluble fiber, weight management, and exercise — not a cardiovascular therapy. Whether to use them, at what dose, and how to check whether they are working are questions for her and her clinician.

Patient B is 64, with a prior heart attack, type 2 diabetes, and an LDL of 105 mg/dL on a moderate-intensity statin. His cardiologist has recommended intensifying lipid-lowering therapy. He read about plant sterols and wants to use them instead. His situation falls outside even that narrow rationale: his risk is high, and the evidence in his situation points toward more intensive LDL lowering — a high-intensity statin, or adding ezetimibe or a PCSK9 inhibitor depending on response. (4,13) The trial that supports adding ezetimibe in his situation does not transfer to a supplement that lowers LDL by a third as much with no outcome data of its own. (4) The question here is not really about the supplement; it is whether choosing it instead of proven therapy delays an intervention his evidence base supports. The hazard is not toxicity. It is false reassurance. What he actually does remains a decision for him and his cardiologist.

Safety

At commonly used doses, plant sterols are not associated with serious adverse effects in the general population. The main safety issue in practice is not toxicity — it is inappropriate use in someone who needs more effective therapy.

Sitosterolemia is the absolute contraindication. This rare autosomal recessive disorder, caused by mutations in the ABCG5 or ABCG8 genes, lets plant sterols accumulate instead of being excreted; gene-based estimates range from roughly 1 in 360,000 to 1 in 2.6 million depending on the gene, and the condition is likely underdiagnosed. (8) It can present with very high LDL-like cholesterol readings, tendon xanthomas, premature atherosclerosis, or unexplained hematologic findings such as low platelets or hemolysis. What lowers cardiovascular risk in most people accelerates it here. Anyone with unexplained premature atherosclerosis or these features should be evaluated before using plant sterols.

Fat-soluble vitamins and carotenoids. Plant sterols modestly reduce absorption of beta-carotene and vitamin E, and small drops in circulating carotenoid levels have been seen in some studies. Clinical deficiency has not been demonstrated in well-nourished people, and the effect is largely offset by eating enough fruits and vegetables. Long-term data are limited.

Children, pregnancy, and breastfeeding. Plant sterols appear in many fortified foods. Therapeutic use in children, during pregnancy, or while breastfeeding is best guided by a clinician, as distinct from incidental food exposure.

Concurrent ezetimibe. Both reduce cholesterol absorption through related pathways, and the added benefit of combining them is uncertain — a question for the prescribing clinician rather than a self-managed stack.

Long-term uncertainty runs both ways. The absence of hard-outcome trials means benefit is unproven; it also means a subtle long-term harm cannot be fully excluded, which is the other half of the unresolved circulating-sterol question above. The reasonable conclusion is not avoidance, but restraint: a defined rationale before use.

Practical Considerations

These points describe how plant sterol products are formulated, used, and studied; whether and how any individual uses them is a question for that person and their clinician.

Reaching a therapeutic dose. Ordinary food supplies only a few hundred milligrams of phytosterols a day, well under the 1.3 to 2.5 grams needed for a meaningful effect. (1,5,6) Fortified products or supplements are required to get there.

Doses reflect the therapeutic range tied to consistent LDL reduction in the 2014 meta-analysis and the Mayo review; actual product values vary by brand and serving. (1,5)

Timing drives the effect. Plant sterols act only when they are in the gut while dietary cholesterol is there; taken on an empty stomach they do little, because the displacement requires both present together.

The delivery vehicle counts. Sterols added to a sugary drink or a calorie-dense spread are not metabolically neutral; the LDL effect cannot be read in isolation from the food carrying it. Replacing butter with a sterol-containing spread produces two effects — less saturated fat and sterol-mediated LDL lowering. Adding a fortified product on top of an unchanged diet produces only the smaller second one.

How any effect is measured. In studies, the LDL response is typically assessed after about 4 to 8 weeks of consistent use with meals. Where the number has not meaningfully moved despite adequate dosing and timing, the data suggest plant sterols are not helping that person. Any effect appears as a measurable change on a lab test, not as a symptom — plant sterols produce no perceptible sensation, so a lab measurement is the only thing that actually answers the question.

Cost in context.

For most people, plant sterols improve a lab value more than they improve the outcomes that value stands for, and they cost more than the better-evidenced drugs. When medication is indicated, both the economics and the evidence point elsewhere.

Common Misconceptions

“An FDA health claim means it’s proven to prevent heart attacks.” It does not. The authorization reflects significant scientific agreement about LDL lowering under defined conditions, not demonstrated event reduction. Confidence in a biomarker is not an outcome verdict.

“Lowering LDL with any product gives the same protection as a statin.” Not as simple as it sounds. Absorption-based LDL lowering does appear to deliver benefit proportional to the LDL drop — that is the real argument for plant sterols. (11) But proportional to a small drop is still small, the proportionality was demonstrated with ezetimibe rather than plant sterols, and plant sterols carry a circulating-sterol question ezetimibe does not. Proven magnitude, mechanism tested directly, and a clean safety profile are exactly what plant sterols lack.

“A natural LDL reduction is still meaningful protection.” A modest LDL reduction is modest regardless of source. In a high-risk patient, 6 to 12% is well short of what changes long-term risk and is not a substitute for therapies that lower LDL by 30 to 50% or more with proven outcomes. (13) “Natural” describes origin, not efficacy.

“Medical societies recognize plant sterols, so they must work.” Some lipid societies recognize them as a dietary LDL-lowering adjunct, hedged explicitly on the absence of outcome trials. (2) That is recognition of the LDL effect, not of event prevention, and the guideline language treats them as part of lifestyle therapy rather than an alternative to proven drugs.

“If plant sterols lower LDL, they must help my heart.” They lower the right number, and probably ApoB with it. Whether that translates into fewer heart attacks — at this magnitude, by this mechanism, given the circulating-sterol question — is precisely what has never been tested for plant sterols. An LDL effect is not, by itself, cardiovascular protection.

The Bottom Line

Plant sterols do one thing well: at the right dose, with meals, in people whose biology responds, they lower LDL cholesterol by 6 to 12%, and they probably lower ApoB along with it. (1) That effect is real and reproducible.

Whether it prevents heart attacks, strokes, or cardiovascular deaths is a question no randomized trial has tested. The closest data, IMPROVE-IT, support the idea of absorption-based LDL lowering — but with a different drug, in a different population, at far greater magnitude, and without the circulating-sterol question that attaches to plant sterols specifically. (4) That analogy is the strongest case for plant sterols, and it remains a case, not a verdict.

The evidence therefore lands differently across three situations. At low cardiovascular risk with a borderline LDL inside a genuine lifestyle approach, plant sterols have a rationale as one component alongside reduced saturated fat, soluble fiber, weight management, and exercise — with a lab check the only way to know whether they are doing anything. In statin intolerance with a real need to lower LDL, ezetimibe lowers more, costs less, carries outcome data, and needs no meal timing. At meaningful cardiovascular risk — prior heart attack, diabetes, multiple risk factors — there is no outcome evidence behind plant sterols, and the recurring way this goes wrong is a supplement standing in for, or delaying, a proven therapy. Which situation fits, and what to do about it, is a matter for each person and their clinician, not a verdict this article delivers.

Across Articles 4, 5, and 6 the same ladder keeps descending. Omega-3 therapy has one formulation with FDA cardiovascular drug approval, built on a randomized outcome trial. CoQ10 has one positive heart failure trial, never replicated, and no approval. Plant sterols have no outcome trial at all and a regulatory designation built entirely on a biomarker. The lab number moved. Whether the disease followed has not been tested — and anything asserted beyond that is a claim the evidence has not earned.

Article 7 turns to soluble fiber — psyllium and oat beta-glucan — the other cardiovascular supplement category with an FDA-authorized health claim, and the one where the dietary rationale and the clinical evidence line up most closely.

Key Terms

ApoB (apolipoprotein B). A protein on each LDL particle. Counting ApoB counts atherogenic particles directly, a more precise measure of risk than the LDL cholesterol concentration alone. Plant sterols lower both LDL-C and ApoB, though their ApoB effect has been studied less than statins’.

Ezetimibe. A prescription drug that blocks the NPC1L1 intestinal cholesterol transporter, lowering LDL by roughly 18 to 24% added to a statin. Carries cardiovascular outcome data in post-ACS patients on a statin (IMPROVE-IT). A more potent, better-evidenced absorption-based option than plant sterols — and, unlike them, not itself a sterol.

FDA-authorized health claim. A statement about disease-risk reduction permitted on labels based on “significant scientific agreement.” A higher bar than structure/function claims, a lower one than drug approval. For plant sterols it rests on LDL lowering, not on demonstrated event prevention.

NPC1L1 (Niemann-Pick C1-Like 1). The intestinal transporter that absorbs cholesterol from food into the bloodstream. Plant sterols, plant stanols, and ezetimibe all interfere with it.

Plant stanols. Saturated derivatives of plant sterols, with similar LDL-lowering effects, even lower systemic absorption, and comparable uses.

Plant sterols. Plant compounds structurally similar to cholesterol that compete with it for intestinal absorption, lowering LDL by 6 to 12% at therapeutic doses.

Sitosterolemia. A rare genetic disorder (ABCG5/ABCG8) causing excessive plant sterol absorption and accumulation, leading to premature atherosclerosis. Plant sterols are contraindicated.

Surrogate endpoint. A measurable marker, such as LDL, used as a proxy for clinical outcomes. LDL’s validation as a surrogate in statin trials does not automatically transfer to every mechanism that lowers it.

References

1. Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr. 2014;112(2):214–219.
2. Gylling H, Plat J, Turley S, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis. 2014;232(2):346–360.
3. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia (ENHANCE). N Engl J Med. 2008;358(14):1431–1443.
4. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). N Engl J Med. 2015;372(25):2387–2397.
5. Katan MB, Grundy SM, Jones P, et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003;78(8):965–978.
6. Ostlund RE Jr. Phytosterols in human nutrition. Annu Rev Nutr. 2002;22:533–549.
7. US Food and Drug Administration. Health claims: plant sterol/stanol esters and risk of coronary heart disease. 21 CFR 101.83. Fed Regist. 2000;65(175):54686–54739.
8. Weingärtner O, Böhm M, Laufs U. Controversial role of plant sterol esters in the management of hypercholesterolaemia. Eur Heart J. 2009;30(4):404–409.
9. Barkas F, Bathrellou E, Nomikos T, Panagiotakos D, Liberopoulos E, Kontogianni MD. Plant sterols and plant stanols in cholesterol management and cardiovascular prevention. Nutrients. 2023;15(13):2845.
10. Ference BA, Graham I, Tokgozoglu L, et al. Impact of lipids on cardiovascular health: JACC health promotion series. J Am Coll Cardiol. 2018;72(10):1141–1156.
11. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–1297.
12. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.
13. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350.
14. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts (PREDIMED). N Engl J Med. 2018;378(25):e34.
15. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92(2):152–160.

HeartBuddi • Your heart. Own it.